DK3541387T3 - Dosis og regime for hdm2-p53-interaktionsinhibitorer - Google Patents

Dosis og regime for hdm2-p53-interaktionsinhibitorer Download PDF

Info

Publication number
DK3541387T3
DK3541387T3 DK17804304.8T DK17804304T DK3541387T3 DK 3541387 T3 DK3541387 T3 DK 3541387T3 DK 17804304 T DK17804304 T DK 17804304T DK 3541387 T3 DK3541387 T3 DK 3541387T3
Authority
DK
Denmark
Prior art keywords
hdm2
regime
dosage
interaction inhibitors
inhibitors
Prior art date
Application number
DK17804304.8T
Other languages
English (en)
Inventor
Stephane Ferretti
Nelson Guerreiro
Sebastien Jeay
Astrid Jullion
Christophe Meille
Jens Wuerthner
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60452703&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3541387(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of DK3541387T3 publication Critical patent/DK3541387T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK17804304.8T 2016-11-15 2017-11-14 Dosis og regime for hdm2-p53-interaktionsinhibitorer DK3541387T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662422144P 2016-11-15 2016-11-15
US201762479391P 2017-03-31 2017-03-31
PCT/IB2017/057097 WO2018092020A1 (en) 2016-11-15 2017-11-14 Dose and regimen for hdm2-p53 interaction inhibitors

Publications (1)

Publication Number Publication Date
DK3541387T3 true DK3541387T3 (da) 2021-07-19

Family

ID=60452703

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17804304.8T DK3541387T3 (da) 2016-11-15 2017-11-14 Dosis og regime for hdm2-p53-interaktionsinhibitorer

Country Status (18)

Country Link
US (1) US10966978B2 (da)
EP (1) EP3541387B1 (da)
JP (1) JP6890659B2 (da)
KR (1) KR102325778B1 (da)
CN (2) CN115252786A (da)
AU (1) AU2017362040C1 (da)
CA (1) CA3043004A1 (da)
DK (1) DK3541387T3 (da)
ES (1) ES2880149T3 (da)
HU (1) HUE055509T2 (da)
IL (1) IL266171B (da)
MX (1) MX2019005623A (da)
PL (1) PL3541387T3 (da)
PT (1) PT3541387T (da)
RU (1) RU2762573C2 (da)
SI (1) SI3541387T1 (da)
TW (1) TWI757367B (da)
WO (1) WO2018092020A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
SI3541387T1 (sl) 2016-11-15 2021-08-31 Novartis Ag Odmerek in režim za zaviralce interakcije HDM2-P53
WO2018178925A1 (en) * 2017-03-31 2018-10-04 Novartis Ag Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
CN110963958A (zh) * 2018-09-30 2020-04-07 上海长森药业有限公司 一种mdm2抑制剂，及其制备方法、药物组合物和应用
JP2022505884A (ja) * 2018-10-30 2022-01-14 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ｐ５３ＷＴ腫瘍の処置の方法
WO2020128898A1 (en) * 2018-12-20 2020-06-25 Novartis Ag Pharmaceutical combinations
WO2021066443A1 (ko) * 2019-09-30 2021-04-08 한미약품 주식회사 Flt3 저해제 및 mdm2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
WO2021211819A1 (en) * 2020-04-16 2021-10-21 Albert Einstein College Of Medicine Inhibition of bax-mediated cell death by eltrombopag

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6548531B2 (en) 2001-02-09 2003-04-15 Hoffmann-La Roche Inc. Method for cancer therapy
US20030139373A1 (en) 2001-11-20 2003-07-24 Breimer Lars Holger Method for cancer therapy
CU24130B1 (es) 2009-12-22 2015-09-29 Novartis Ag Isoquinolinonas y quinazolinonas sustituidas
US8440693B2 (en) * 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
WO2012065022A2 (en) 2010-11-12 2012-05-18 The Regents Of The University Of Michigan Spiro-oxindole mdm2 antagonists
WO2013096150A1 (en) 2011-12-21 2013-06-27 Merck Sharp & Dohme Corp. Substituted piperidines as hdm2 inhibitors
US8815926B2 (en) * 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
US20130245089A1 (en) * 2012-03-19 2013-09-19 Hoffmann-La Roche Inc. Method for administration
CA2926307C (en) 2013-12-05 2021-11-16 F. Hoffmann-La Roche Ag Novel combination treatment for acute myeloid leukemia (aml)
TW201613576A (en) * 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
US20170340733A1 (en) 2014-12-19 2017-11-30 Novartis Ag Combination therapies
CA2981753A1 (en) 2015-02-06 2016-08-11 Unity Biotechnology, Inc. Compounds and uses in treatment of senescence-associated conditions
AU2016308704B2 (en) 2015-08-14 2019-06-20 Novartis Ag MDM2 inhibitors for treating uveal melanoma
SI3541387T1 (sl) 2016-11-15 2021-08-31 Novartis Ag Odmerek in režim za zaviralce interakcije HDM2-P53
WO2018178925A1 (en) 2017-03-31 2018-10-04 Novartis Ag Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors

Also Published As

Publication number Publication date
CN115252786A (zh) 2022-11-01
AU2017362040A1 (en) 2019-05-02
ES2880149T3 (es) 2021-11-23
RU2762573C2 (ru) 2021-12-21
IL266171A (en) 2019-06-30
SI3541387T1 (sl) 2021-08-31
PL3541387T3 (pl) 2021-10-25
RU2019118261A3 (da) 2021-03-18
AU2017362040B2 (en) 2020-04-30
PT3541387T (pt) 2021-07-14
IL266171B (en) 2021-12-01
MX2019005623A (es) 2019-08-14
CN109982702A (zh) 2019-07-05
US10966978B2 (en) 2021-04-06
JP6890659B2 (ja) 2021-06-18
US20190298719A1 (en) 2019-10-03
KR20190084292A (ko) 2019-07-16
CA3043004A1 (en) 2018-05-24
AU2017362040C1 (en) 2020-09-10
EP3541387A1 (en) 2019-09-25
TW201822817A (zh) 2018-07-01
HUE055509T2 (hu) 2021-12-28
RU2019118261A (ru) 2020-12-17
TWI757367B (zh) 2022-03-11
KR102325778B1 (ko) 2021-11-12
WO2018092020A1 (en) 2018-05-24
JP2020500190A (ja) 2020-01-09
EP3541387B1 (en) 2021-04-21

Similar Documents

Publication Publication Date Title
DK3541387T3 (da) Dosis og regime for hdm2-p53-interaktionsinhibitorer
DK3368069T3 (da) Anvendelse af myostatininhibitorer og kombinationsterapier
DK3386484T3 (da) Sammensætninger og fremgangsmåder til afgivelse af terapeutiske midler
DK3565550T3 (da) Farmaceutiske sammensætninger omfattende meloxicam og rizatriptan
DK3317284T3 (da) Benzoxazepin-oxazolidinonforbindelser og fremgangsmåder til anvendelse
DK3464282T3 (da) Heteroarylsubstituerede pyridiner og fremgangsmåder til anvendelse
DK3350157T3 (da) Forbindelser og sammensætninger til intracellulær afgivelse af terapeutiske midler
DK3521289T3 (da) Mnk-inhibitorer og fremgangsmåder forbundet dermed
DK3548033T3 (da) Forbindelser og deres fremgangsmåde til anvendelse
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
DK3295951T3 (da) Anti-pvrig-antistoffer og fremgangsmåder for anvendelse
DK3234133T3 (da) Crispr-baserede sammensætninger og fremgangsmåder til anvendelse
DK3452485T3 (da) Arginasehæmmere og deres terapeutiske anvendelser
DK3177608T3 (da) Proteinkinase-C-hæmmere og fremgangsmåder til anvendelse deraf
DK3227310T3 (da) Heterobifunktionelle inhibitorer af e-selektiner og cxcr4-kemokin-receptorer
DK3487505T3 (da) Indgivelse og dosering af diaminophenothiaziner
DK3263565T3 (da) Cyklisk aminderivat og farmaceutisk anvendelse deraf
DK3394065T3 (da) Tetrahydropyranyl-amino-pyrrolopyrimidinon og fremgangsmåder til anvendelse deraf
DK3532459T3 (da) Lsd1-hæmmere og medicinske anvendelser deraf
DK3089971T3 (da) Forbindelser og fremgangsmåder til anvendelse
DK3543240T3 (da) URAT1-inhibitor og anvendelse deraf
DK3278803T3 (da) Fast farmaceutisk doseringsform af PARP-inhibitor, og anvendelse af fast farmaceutisk doseringsform af PARP-inhibitor
DK3380525T3 (da) Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
DK3107902T3 (da) Forbindelser og fremgangsmåder til at hæmme fascin
DK3621694T3 (da) Lrrc33-inhibitorer og anvendelse heraf